You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

NYSTATIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nystatin patents expire, and when can generic versions of Nystatin launch?

Nystatin is a drug marketed by Actavis Mid Atlantic, Cosette, Crown Labs Inc, Fougera Pharms, Macleods Pharms Ltd, Padagis Us, Strides Pharma, Taro, Torrent, Lyne, Zydus Lifesciences, Paddock Llc, Adrastea Pharma, Dr Reddys Labs Sa, Epic Pharma Llc, Lupin, Nesher Pharms, Upsher Smith Labs, Zydus Pharms, Alpharma Us Pharms, Fougera Pharms Inc, G And W Labs Inc, Genus, Leading, MLV, Morton Grove, Pai Holdings, Pharm Assoc, Pharmaderm, Pharmafair, Teva, Vistapharm, Wockhardt Bio Ag, Chartwell Rx, Heritage Pharms, Quantum Pharmics, Sandoz, Sun Pharm Industries, Watson Labs, Fougera, Odyssey Pharms, Alembic, Amneal, Dr Reddys, Glenmark Pharms Ltd, Lupin Ltd, Padagis Israel, Perrigo New York, Pai Holdings Pharm, and Rising. and is included in ninety NDAs.

The generic ingredient in NYSTATIN is nystatin; triamcinolone acetonide. There are eight drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the nystatin; triamcinolone acetonide profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NYSTATIN?
  • What are the global sales for NYSTATIN?
  • What is Average Wholesale Price for NYSTATIN?
Drug patent expirations by year for NYSTATIN
Drug Prices for NYSTATIN

See drug prices for NYSTATIN

Drug Sales Revenue Trends for NYSTATIN

See drug sales revenues for NYSTATIN

Recent Clinical Trials for NYSTATIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Santiago de CompostelaN/A
University of RochesterPhase 1
Minia UniversityEarly Phase 1

See all NYSTATIN clinical trials

Pharmacology for NYSTATIN
Drug ClassPolyene Antifungal
Medical Subject Heading (MeSH) Categories for NYSTATIN

US Patents and Regulatory Information for NYSTATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro NYSTATIN AND TRIAMCINOLONE ACETONIDE nystatin; triamcinolone acetonide CREAM;TOPICAL 062364-001 Dec 22, 1987 AT RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva NYSTATIN nystatin SUSPENSION;ORAL 062670-001 Jun 18, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Genus NYSTATIN nystatin SUSPENSION;ORAL 065148-001 Jun 28, 2005 AA RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising NYSTATIN AND TRIAMCINOLONE ACETONIDE nystatin; triamcinolone acetonide OINTMENT;TOPICAL 206785-001 Dec 29, 2016 AT RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.